Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Filings
44 filings of ZYDUSLIFE since November 2024; the newest 40 below.
presentation 12, board outcome 11, transcript 9, buyback 6, credit rating 2, results 2
| Filed | Type | Subject | |
|---|---|---|---|
| 07 Nov 2026 | transcript Capex, Guidance, Legal, Results | Zydus Lifesciences Limited has informed the Exchange about TranscriptAI summaryZydus Lifesciences filed the transcript of its Q2 FY27 post-results earnings call held on November 4, 2026. Management said consolidated revenue was ₹79.1 billion, up 29% year-on-year, with EBITDA of ₹18.9 billion (24% margin) and net profit of ₹9.3 billion; net debt to EBITDA was 0.62 times. Management said India branded formulations grew 19% year-on-year, North America revenue was ₹33.1 billion (up 21%), and consumer wellness revenue was ₹11.2 billion (up 76%). Management said the Saroglitazar US launch is expected in March, with commercial expense around $100 million every year, and that the USFDA goal date is November. Management said USFDA inspections at SEZ-II Ahmedabad and Moraiya concluded with one and five observations respectively. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Nov 2026 | presentation Capex, Legal, Results | Zydus Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryZydus Lifesciences filed its investor presentation on unaudited results for the quarter and half year ended September 30, 2026 (Q2 FY27). Total revenues from operations were Rs. 79,096 mn, up 29% YoY; net profit was Rs. 9,255 mn, and EBITDA was Rs. 18,945 mn at a 24.0% margin. Organic capex for the quarter was Rs. 4,655 mn; net debt was Rs. 51,998 mn as at September 30, 2026. Management said India branded formulations grew 19% YoY, North America formulations grew 20.8% YoY, and USFDA inspections at SEZ II, Ahmedabad and Moraiya concluded with one and five observations. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Nov 2026 | board outcome Legal, Management change | Zydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026.AI summaryZydus Lifesciences intimated under Regulation 30 of the Listing Regulations that its Board, at its meeting held on November 4, 2026, approved the appointment of Walker Chandiok & Co LLP (Firm Registration No. 001076N/N500013) as statutory auditors. The appointment replaces Deloitte Haskins and Sells LLP, which completes its second consecutive five-year term at the conclusion of the 32nd AGM for FY 2026-27, under mandatory auditor rotation under section 139(2) of the Companies Act, 2013. Walker Chandiok's proposed first term is five years, from the conclusion of the 32nd AGM (FY 2026-27) to the conclusion of the 37th AGM (FY 2031-32), subject to member approval at the 32nd AGM. The Board meeting commenced at 10:50 a.m. and concluded at 12:10 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Nov 2026 | board outcome Results | Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryZydus Lifesciences board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026 at its meeting held November 4, 2026; Deloitte Haskins & Sells issued limited review reports. Standalone Q2 FY27 total revenue from operations was INR 34,820 million and net profit was INR 7,145 million, against INR 28,712 million revenue and INR 11,566 million net profit in the year-ago quarter (September 30, 2025). Standalone half-year total revenue from operations was INR 63,542 million and net profit was INR 10,541 million (half year ended September 30, 2025: INR 54,595 million and INR 15,413 million). Other income in the quarter included dividend from subsidiaries and joint ventures of INR 220 million, versus INR 4,198 million in the year-ago quarter. Exceptional item of INR 19 million in the quarter relates to torrential rain damage at Ahmedabad facilities, net of insurance claim receivable; the company has lodged insurance claims for an estimated loss of INR 373 million. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Sep 2026 | credit rating Rating | Zydus Lifesciences Limited has informed the Exchange about Credit RatingAI summaryZydus Lifesciences intimated under Regulation 30 that CRISIL Ratings Limited reviewed and reaffirmed its credit ratings by letters dated September 10, 2026. Bank facilities of Rs. 4,724 crore: long-term rating CRISIL AAA/Stable and short-term rating CRISIL A1+, both reaffirmed. Commercial papers of Rs. 200 crore rated CRISIL A1+ (reaffirmed); non-convertible debentures of Rs. 50 crore rated CRISIL AAA/Stable (reaffirmed); a further Rs. 75 crore instrument rated CRISIL AAA/Stable (reaffirmed). The company states there are no outstanding CPs or NCDs as on the date of the filing; the rating letter and rationale are enclosed. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Aug 2026 | presentation | Zydus Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryZydus Lifesciences filed its corporate investor presentation (dated August 2026) for investor meetings between August 24 and August 26, 2026, referring to an earlier letter dated August 17, 2026. The presentation shows FY26 revenue of US$3.02bn and FY26 EBITDA of US$959mn (at FY26 average exchange rate of INR 88.33/US$), and a market cap of US$11.7bn as on August 21, 2026. Business mix in FY26 by segment: India Formulations 24.6%, North America Formulations 43.7%, IM Formulations 11.5%, Consumer Wellness 14.6%, MedTech 2.9%, Others 2.6%. The company reports 44 manufacturing facilities, 10 R&D centres and around 30k Zydans globally, with FY26 R&D spend of US$257mn. The presentation states 23 products under development, 7 under regulatory review and 3 approved products in its pipeline, and that Saroglitazar NDA for PBC has received USFDA priority review. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Aug 2026 | transcript Acquisition, Guidance, Legal, Results | Zydus Lifesciences Limited has informed the Exchange about TranscriptAI summaryZydus Lifesciences filed the transcript of its Q1 FY27 post-results earnings call held on August 11, 2026. Management said consolidated revenue was ₹80.2 billion, up 22% year-on-year, with EBITDA of ₹19.3 billion (EBITDA margin 24.1%) and net profit of ₹9.4 billion; net debt to EBITDA was 0.7 times as on June 30, 2026. Management said India branded formulations grew 20% year-on-year, consumer wellness revenue rose 67% year-on-year to ₹14.3 billion, and international formulations grew 34% to ₹9.7 billion. Management said it continues to guide for strong double-digit revenue growth for FY27 and still guides to a 24%+ margin, with Saro-related spend increasing in the second half. Management said the Assertio Holdings acquisition was completed and Saroglitazar's NDA was granted priority review by the USFDA. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Aug 2026 | presentation Acquisition, Capex, Legal, Results | Zydus Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryZydus Lifesciences filed its Q1 FY27 earnings investor presentation (quarter ended June 30, 2026) under Regulation 30 read with Regulation 46 of the Listing Regulations. Total revenues from operations were Rs. 80,170 mn, up 22% YoY; EBITDA was Rs. 19,294 mn with a 24.1% margin, down 770 bps YoY; reported PAT was Rs. 8,000-range figure not clearly legible, shown as Rs. 5,852 mn organic capex and Rs. 59,041 mn net debt as at June 30, 2026. The presentation states an injectable manufacturing facility at Zydus Biotech Park received a VAI classification after a GMP inspection in April-May 2026. Management said India branded formulations outpaced market growth, North America formulations grew sequentially on volume expansion and new launches, and the company completed the acquisition of Assertio Holdings Inc. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Aug 2026 | board outcome Results | Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryZydus Lifesciences Limited filed the outcome of its board meeting held on August 11, 2026, approving unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Standalone total income for the quarter ended June 30, 2026 was INR 29,959 million, against INR 27,454 million in the year-ago quarter. Standalone net profit for the quarter ended June 30, 2026 was INR 3,396 million, against INR 3,847 million in the year-ago quarter; basic EPS was INR 3.38 (not annualised). Other income for the quarter included INR 3,333 million of dividend from subsidiaries and joint ventures for the quarter ended March 31, 2026 (note 3 refers to the March quarter figure). The trading window remains closed until August 13, 2026 and reopens on August 14, 2026 for directors and designated persons. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 01 Jun 2026 | buyback Dividend / buy-back | Zydus Lifesciences Limited has informed the Exchange about BuybackAI summaryZydus Lifesciences filed the revised letter of offer for its buyback of up to 87,30,158 equity shares (0.87% of paid-up capital) at INR 1,260 per share via tender offer, for an aggregate amount not exceeding INR 1,100 crore. Paragraph 19.5.4 of the letter of offer dated May 31, 2026 has been restated; all other terms are unchanged. Record date is May 29, 2026; the buyback opens on June 4, 2026 and closes on June 10, 2026. Buyback entitlement is 5 shares for every 49 shares held for the reserved small shareholder category, and 7 shares for every 937 shares held for the general category. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 01 Jun 2026 | buyback Dividend / buy-back, Legal | Zydus Lifesciences Limited has informed the Exchange about BuybackAI summaryZydus Lifesciences submitted a restated Letter of Offer dated May 31, 2026 for its buyback; only paragraph 19.5.4 was restated and all other terms are unchanged. The buyback covers up to 87,30,158 fully paid-up equity shares (face value INR 1) at INR 1,260 per share through the tender offer route, for an aggregate amount not exceeding INR 1,100 crore, excluding transaction costs. The record date is May 29, 2026; the buyback opens on June 4, 2026 and closes on June 10, 2026. Buyback entitlement is 5 shares for every 49 held for the Reserved Category for Small Shareholders, and 7 shares for every 937 held for the General Category. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 31 May 2026 | buyback Dividend / buy-back, Legal | Zydus Lifesciences Limited has informed the Exchange about BuybackAI summaryZydus Lifesciences filed the letter of offer dated May 31, 2026 for a buyback of not exceeding 87,30,158 equity shares (face value INR 1) at INR 1,260 per share, aggregate not exceeding INR 1,100 crore, via tender offer route. Record date for the buyback is May 29, 2026; the buyback opens on June 4, 2026 and closes on June 10, 2026, with last date for receipt of tender forms also June 10, 2026 and last date of settlement June 17, 2026. Buyback Size is 5.16% of standalone and 3.84% of consolidated paid-up capital plus free reserves as at March 31, 2026, within the 10% statutory limit. Buyback entitlement ratio is 5 shares for every 49 held for the reserved small shareholders category and 7 shares for every 937 held for the general category. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 May 2026 | buyback Dividend / buy-back | Zydus Lifesciences Limited has informed the Exchange about newspaper publication of addendum to Public Announcement for BuybackAI summaryZydus Lifesciences filed an addendum dated May 28, 2026 to the public announcement for its buyback of equity shares (face value INR 1) through the tender offer route. The buyback price was increased from INR 1,150 to INR 1,260 per equity share, and the maximum number of shares to be bought back was reduced from 95,65,217 to 87,30,158 shares (up to 0.87% of paid-up share capital). The addendum was published on May 28, 2026 in Financial Express (English, all editions), Jansatta (Hindi, all editions) and Financial Express (Gujarati, Ahmedabad). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 May 2026 | buyback Dividend / buy-back | Zydus Lifesciences Limited has informed the Exchange about addendum to the Public Announcement for the buyback of equity sharesAI summaryZydus Lifesciences filed an addendum to its public announcement for the tender offer buyback of equity shares. The Buyback Committee, at its May 27, 2026 meeting, increased the buyback price from INR 1,150 to INR 1,260 per equity share. The maximum number of equity shares to be bought back was reduced from 95,65,217 to 87,30,158 shares, representing up to 0.87% of paid-up share capital. The aggregate buyback size stated in the original announcement was not exceeding INR 1,100 crore. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 May 2026 | transcript Acquisition, Guidance, Legal, Results | Zydus Lifesciences Limited has informed the Exchange about TranscriptAI summaryZydus Lifesciences filed the transcript of its Q4 FY26 post-results earnings call held on May 19, 2026. Management said FY26 consolidated revenue was ₹271.5 billion, up 17% year-on-year, with consolidated EBITDA of ₹84.8 billion (up 20%) and an EBITDA margin of 31.2%; net profit adjusted for exceptional items was ₹54.6 billion, up 15%. For Q4 FY26, consolidated revenue was ₹75.9 billion (up 16% year-on-year) with EBITDA margin of 33.7%; net debt to EBITDA stood at 0.5 times as on March 31, 2026. Management said it expects high-teens consolidated revenue growth in FY27 and single-digit growth in the North American business despite a high FY26 base. Management referred to the proposed acquisition of Assertio Holdings for its US specialty oncology strategy, and to the acquisitions of Comfort Click Limited and Amplitude Surgical. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 May 2026 | buyback Dividend / buy-back, Legal | Zydus Lifesciences Limited has informed the Exchange about BuybackAI summaryZydus Lifesciences' board approved a buyback of up to 95,65,217 fully paid-up equity shares (face value INR 1 each), about 0.95% of paid-up equity capital as on March 31, 2026, at INR 1,150 per share. The aggregate buyback size is not exceeding INR 1,100,00,00,000 (INR 1,100 crore), excluding transaction costs, and is to be done through the tender offer route. The record date for determining eligible shareholders is Friday, May 29, 2026. The buyback is to be funded from securities premium, free reserves and/or other permitted sources, and the company will not use borrowed funds to pay shareholders. Dhaval N. Soni, Company Secretary and Compliance Officer, was appointed Compliance Officer for the buyback. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 May 2026 | presentation Acquisition, Capex, Dividend / buy-back, Results | Zydus Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryZydus Lifesciences filed its Q4 and FY26 earnings investor presentation (dated 19 May 2026) on audited results for the quarter/year ended 31 March 2026. Q4 FY26 total revenues from operations were Rs. 75,870 mn, up 16% YoY; FY26 revenues were Rs. 2,71,484 mn versus Rs. 2,32,415 mn in FY25. Q4 FY26 EBITDA was Rs. 25,544 mn with a 33.7% margin, up 110 bps YoY; Q4 PAT excluding exceptional items was Rs. 15,929 mn, up 15% YoY. Q4 FY26 organic capex was Rs. 3,577 mn; net debt was Rs. 43,050 mn as at 31 March 2026. The Board approved a buy-back of up to Rs. 11,000 mn at Rs. 1,150 per equity share, a 16% premium to the 18 May 2026 closing price; the presentation also notes an agreement to acquire Assertio Holdings Inc. for US$166 mn. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 May 2026 | board outcome Dividend / buy-back | Zydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on May 19, 2026.AI summaryZydus Lifesciences' board, at a meeting on May 19, 2026, approved a proposal to buy back up to 95,65,217 equity shares (0.95% of paid-up capital) at INR 1,150 per share, for an aggregate amount not exceeding INR 1,100 crore, through the tender offer route. The buyback size is 5.16% of standalone and 3.84% of consolidated free reserves plus share capital as at March 31, 2026, per the filing. The board set May 29, 2026 as the record date and formed a buyback committee with delegated powers. The public announcement and letter of offer will be released later under the Buyback Regulations. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 May 2026 | dividend Dividend / buy-back, Results | Zydus Lifesciences Limited has informed the Exchange that Board of Directors at its meeting held on May 19, 2026, recommended Final Dividend of Rs. 1.00 per equity share.AI summaryZydus Lifesciences' board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 at its meeting held on May 19, 2026. Statutory auditor Deloitte Haskins & Sells LLP has issued audit reports on both standalone and consolidated results with an unmodified opinion. The board recommended a final dividend of Re. 1/- (100%) per equity share of Re. 1/- each, subject to shareholder approval at the AGM scheduled for August 11, 2026. The trading window under insider trading regulations remains closed till May 21, 2026, and reopens on May 22, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 May 2026 | board outcome Dividend / buy-back, Results | Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryZydus Lifesciences' board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 at its meeting held on May 19, 2026 (noon to 2:00 p.m.). Statutory auditor Deloitte Haskins & Sells LLP issued audit reports on the standalone and consolidated results with an unmodified opinion. The board recommended a final dividend of Re. 1/- (100%) per equity share of Re. 1/- each, subject to shareholder approval at the AGM scheduled for August 11, 2026. The trading window remains closed until May 21, 2026 and reopens on May 22, 2026 for directors and designated persons. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 Feb 2026 | transcript Acquisition, Guidance, Legal, Results | Zydus Lifesciences Limited has informed the Exchange about TranscriptAI summaryZydus Lifesciences filed the transcript of its Q3 FY26 post-results earnings call held on February 10, 2026. Management reported Q3 consolidated revenue of ₹68.6 billion, up 30% year-on-year, and EBITDA of ₹18.2 billion, up 31%, with a 26.5% EBITDA margin. Adjusted net profit for the quarter was ₹11.1 billion, up 9% year-on-year, after adjusting for a labor code exceptional expense and acquisition-related costs. Management said North America formulations revenue was ₹28 billion, up 16%, and India branded formulations grew 14%; Consumer Wellness revenue was ₹9.6 billion, up 113% with Comfort Click consolidation. On the call, management said Agenus CDMO commercialization is expected from 2H FY27, and that the current other-expenses run rate excluding R&D is about ₹1,750-₹1,800 crore, excluding Saroglitazar launch costs. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Feb 2026 | presentation Capex, Legal, Results | Zydus Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryZydus Lifesciences filed an investor presentation on its unaudited results for the quarter and nine months ended December 31, 2025 (Q3 & 9M FY26), dated February 9, 2026. Q3 FY26 total revenues from operations were Rs. 68,645 mn, up 30% YoY; EBITDA was Rs. 11,109 mn, up 9% YoY, with EBITDA margin at 26.5%, up 20 bps YoY. Q3 FY26 PAT excluding exceptional items was Rs. 11,109 mn... see note; organic capex for the quarter was Rs. 4,637 mn. Net debt was Rs. 28,728 mn at December 31, 2025, against net cash of Rs. 48,880 mn at March 31, 2025. Management said India branded formulations sustained growth and outpaced the market, US base business grew on volume expansion and new launches, and Consumer Wellness held dominant market share in key brands. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Feb 2026 | board outcome Legal, Results | Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryBoard of Zydus Lifesciences approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, on February 9, 2026. Standalone revenue from operations for Q3 FY26 was INR 22,836 million, down from INR 25,159 million a year earlier; net profit was INR 2,965 million versus INR 4,706 million a year earlier. Nine-month standalone net profit was INR 18,378 million versus INR 29,612 million in the prior-year period. Q3 profit includes a one-time exceptional item of INR 601 million for higher gratuity and leave encashment liability under the New Labour Codes effective November 21, 2025. Trading window stays closed until February 11, 2026 and reopens on February 12, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 25 Nov 2025 | presentation | Zydus Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryZydus Lifesciences filed its November 2025 corporate presentation under Regulation 30 of the SEBI Listing Regulations; it is also posted on the company website. Presentation cites FY25 revenue of US$2.75bn and FY25 EBITDA of US$835mn (at average exchange rate INR 84.57/US$). H1FY26 pharma revenue is shown as US$1.44bn (average exchange rate INR 86.47/US$), with US formulations at 47.4% and India formulations at 24.9% of the business mix. Company states it is #1 in Oncology in India (IQVIA MAT Sep'25) and #4 in the US generics market by prescriptions. Presentation outlines pipeline items, including saroglitazar US NDA filing (PBC) planned and 16 biosimilars approved and 13 launched in India. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Nov 2025 | transcript Acquisition, Capex, Dividend / buy-back, Guidance, Results | Zydus Lifesciences Limited has informed the Exchange about TranscriptAI summaryZydus Lifesciences filed the transcript of its Q2 FY26 post-results earnings call held on November 6, 2025. Management said consolidated revenue was Rs. 61.2 billion, up 17% year-on-year, with EBITDA of Rs. 20.2 billion (margin 32.9%) and net profit of Rs. 12.6 billion, up 38% year-on-year. Management said US revenue was Rs. 27.4 billion, up 14% year-on-year, and India branded formulations grew 9% year-on-year. Management said it acquired UK-based Comfort Click Limited, its first international acquisition, and completed 100% acquisition of Amplitude Surgical. Management said the proposed fundraising is aimed at deleveraging the balance sheet, and that it has no immediate actionable deal; it also said it is on track to achieve its targeted top-line growth and profitability for FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2025 | presentation Acquisition, Capex, Legal, Results | Zydus Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryZydus Lifesciences filed its investor presentation on unaudited results for the quarter and half year ended September 30, 2025 (Q2 & H1 FY26). Total revenues from operations were Rs. 61,232 mn in Q2 FY26, up 17% YoY; EBITDA was Rs. 20,158 mn with a margin of 32.9%, up 500 bps YoY; net profit was Rs. 12,586 mn, up 38% YoY. Organic capex for the quarter was Rs. 4,911 mn; net debt was Rs. 22,787 mn at 30-Sep-25 versus net cash of Rs. 48,880 mn at 31-Mar-25. Management said the Consumer Wellness business made its first international acquisition, of UK-based Comfort Click Ltd (CCL), and that US formulations delivered strong double-digit YoY growth. Management said the Oncology injectable facility at SEZ Ahmedabad and the Baddi formulations facility received USFDA Establishment Inspection Reports with Voluntary Action Indicated (VAI) status. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2025 | board outcome Capex, Dividend / buy-back | Zydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on November 06, 2025.AI summaryZydus Lifesciences' board, at a meeting held on November 6, 2025, approved raising funds of up to Rs. 5,000 crore through issuance of eligible securities. The fundraise may be done in one or more tranches via QIP, rights issue, preferential allotment, private placement, or any combination or other permitted method. The issuance is subject to shareholder approval and regulatory/statutory approvals; a board committee is authorised to take decisions. The board approved a postal ballot notice seeking member approval; the notice will be sent separately. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 Nov 2025 | board outcome Results | Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryBoard of Zydus Lifesciences approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, on November 6, 2025, with limited review reports from Deloitte Haskins & Sells LLP. Standalone Q2 FY26 net profit was INR 11,566 million, against INR 3,847 million in Q1 FY26 and INR 7,898 million in Q2 FY25 (figures as printed, in INR million). Standalone Q2 FY26 total revenue from operations was INR 28,712 million, against INR 26,206 million in the corresponding quarter last year; other income included dividend from subsidiaries and joint ventures of INR 4,198 million. Standalone basic EPS for Q2 FY26 was Rs. 11.49. The trading window remains closed till November 8, 2025, and reopens on November 10, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 Aug 2025 | transcript Acquisition, Guidance, Results | Zydus Lifesciences Limited has informed the Exchange about TranscriptAI summaryZydus Lifesciences filed the transcript of its Q1 FY26 post-results earnings call held on August 12, 2025, under Regulations 30 and 46(2)(oa) of the Listing Regulations. Management reported consolidated revenue of ₹65.7 billion, up 6% year-on-year, EBITDA of ₹20.9 billion at a 31.8% margin, and net profit of ₹14.7 billion, up 3% year-on-year. US business revenue was ₹31.8 billion, up 3% year-on-year; India business was 37% of total revenue, growing 6% year-on-year; International markets formulations revenue was ₹7.3 billion, up 37% year-on-year. Net cash position was ₹56.3 billion as of June 30, 2025, against ₹48.8 billion as of March 31, 2025. Management said it maintains FY26 US growth guidance of single-digit growth despite Revlimid price pressure, and that Saroglitazar data readout is expected around the end of the second or beginning of the third quarter, with a possible launch in FY27 if data is promising. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Aug 2025 | presentation Capex, Legal, Results | Zydus Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryZydus Lifesciences filed its Q1 FY26 earnings investor presentation (quarter ended June 30, 2025) on August 12, 2025. Total revenues from operations were Rs. 65,737 mn, up 6% YoY; EBITDA was Rs. 14,668 mn with a 31.8% margin, flat YoY; net profit (PAT ex. exceptional) was Rs. 9,112 mn... [see note] Net cash stood at Rs. 56,312 mn at 30-Jun-25 versus Rs. 48,836 mn at 31-Mar-25; organic capex for the quarter was Rs. 4,020 mn. Management said India branded formulations sustained growth and outpaced the market, US formulations grew YoY and QoQ on a high base, and Consumer Wellness was affected by early monsoon conditions. Two API facilities at Ankleshwar and Dabhasa received USFDA Establishment Inspection Reports against inspections in March and April 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Aug 2025 | board outcome Results | Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryBoard approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, on August 12, 2025, after Audit Committee review; Deloitte Haskins & Sells LLP issued limited review reports. Standalone revenue from operations for Q1 FY26 was INR 25,883 million, versus INR 58,196 million in the March 31, 2025 quarter and INR 41,602 million in the June 30, 2024 quarter. Standalone net profit for the quarter was INR 3,847 million, versus INR 28,137 million in the March 2025 quarter and INR 17,008 million in the June 2024 quarter; basic EPS was Rs. 3.82. The trading window remains closed till August 14, 2025 and reopens on August 18, 2025 for directors and designated persons. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Jun 2025 | presentation Guidance | Zydus Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryZydus Lifesciences filed its June 2025 investor presentation, to be used at investor conferences between June 25 and June 27, 2025. The presentation gives FY25 revenues of US$2.75 bn (Rs 225.7 bn) and EBITDA of US$835 mn (30.4% margin), with R&D spend of US$219 mn (8.0% of revenues). Sales split by segment: India 38%, US 49%, IM 10%, API 2%, Alliances 1%; Consumer Wellness is 12% and Formulations 26%. The company reports a market cap of US$11.3 bn as on June 24, 2025, 38 manufacturing facilities, 7 R&D centres, and 207 US generic products under development for filing over the next five years. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 May 2025 | transcript Acquisition, Legal, Results | Zydus Lifesciences Limited has informed the Exchange about TranscriptAI summaryZydus Lifesciences filed the transcript of its Q4 FY25 post-results earnings call held on May 20, 2025. Management said FY25 consolidated revenue was Rs 232.4 billion, up 19% year-on-year, with operating margin of 30.4% (up 290 bps) and EBITDA up 31% to Rs 70.6 billion. Management reported FY25 adjusted net profit of Rs 47.5 billion, up 22%, and a net cash position of Rs 48.8 billion as at March 31, 2025. For Q4 FY25, consolidated revenue was Rs 65.3 billion, up 18% year-on-year, with EBITDA of Rs 21.3 billion and an EBITDA margin of 32.6%. Management also noted the acquisition of a majority stake in Amplitude Surgical SA, France, under a share purchase agreement. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 May 2025 | presentation Capex, Legal, Results | Zydus Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryZydus Lifesciences filed its investor presentation on audited results for Q4 and full year FY25 (quarter/year ended March 31, 2025), dated May 20, 2025. Q4 FY25 total revenues from operations were Rs. 65,279 mn, up 18% YoY; full-year FY25 revenues were Rs. 2,32,415 mn versus Rs. 1,95,474 mn in FY24. Q4 FY25 EBITDA was Rs. 21,255 mn at a 32.6% margin, up 310 bps YoY; Q4 FY25 PAT excluding exceptional items was Rs. 13,905 mn, up 18% YoY. Management stated net cash was Rs. 48,836 mn at March 31, 2025 versus Rs. 8,561 mn a year earlier, and organic capex for the quarter was Rs. 3,202 mn. Management said the Ambernath API facility received an EIR with No Action Indicated (NAI) status following a February 2025 inspection, concluded without observations. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 May 2025 | dividend Dividend / buy-back, Results | Zydus Lifesciences Limited has informed the Exchange that Board of Directors at its meeting held on May 20, 2025, recommended Final Dividend of Rs. 11.00 per equity share.AI summaryThe Board of Zydus Lifesciences approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, at a meeting held on May 20, 2025. Deloitte Haskins & Sells LLP, the statutory auditors, issued audit reports on both sets of results with an unmodified opinion. The Board recommended a final dividend of Rs. 11 per equity share of Re. 1 each (1100%), subject to shareholder approval at the AGM scheduled for August 12, 2025. The trading window remains closed until May 22, 2025, and reopens on May 23, 2025, for directors and designated persons. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 May 2025 | board outcome Dividend / buy-back, Results | Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.AI summaryThe Board of Zydus Lifesciences approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2025 at its meeting held on May 20, 2025. Deloitte Haskins & Sells LLP, the statutory auditors, issued unmodified audit reports on the standalone and consolidated results for the year ended March 31, 2025. The Board recommended a final dividend of Rs. 11 per equity share of Re. 1 each (1100%), subject to shareholder approval at the AGM scheduled for August 12, 2025. The trading window remains closed till May 22, 2025, and reopens on May 23, 2025, for Directors and Designated Persons. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Mar 2025 | presentation Acquisition | Zydus Lifesciences Limited has informed the Exchange about Investor PresentationAI summaryZydus Lifesciences filed an investor presentation dated March 2025 on its plans to acquire Amplitude Surgical SA, France, a listed company. The presentation positions the acquisition as Zydus's foray into the global MedTech space, alongside organic initiatives. It cites Zydus FY24 global revenue of US$2.30 bn and FY24 EBITDA of US$650 mn (27.5% margin), with the company's market capitalisation at US$2.35 bn as of March 10, 2025. It cites the global medical devices market expected to reach US$670 bn by 2029E, and the Indian MedTech market expected to reach US$50 bn by 2030E from US$12 bn in FY24E. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Mar 2025 | board outcome Acquisition, Legal | Zydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on March 11, 2025.AI summaryZydus Lifesciences' board approved entering agreements to acquire a controlling 85.6% stake in Amplitude Surgical SA, France (listed on Euronext Paris) at EUR 6.25 per share, for a consideration of EUR 256.8 million. Post-closing, the company would make a mandatory simplified cash tender offer for the remaining shares at the same price, followed by a squeeze-out and delisting if conditions are met. Target's turnover as on June 30, 2024 was EUR 106 million (audited IFRS consolidated figures). The acquisition is not a related party transaction; the target operates in Medical Technology (orthopaedics). The deal is subject to consultation with the target's Social and Economic Committee and approval of the French Minister of Economy. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 11 Feb 2025 | transcript Guidance, Results | Zydus Lifesciences Limited has informed the Exchange about TranscriptAI summaryZydus Lifesciences filed the transcript of its Q3 FY25 post-results earnings call held on February 5, 2025. Management reported consolidated revenue of ₹52.7 billion, up 17% year-on-year, and EBITDA of ₹13.9 billion, up 26%, with reported EBITDA margin of 26.3% versus 24.5%. Net profit for the quarter was ₹10.2 billion, up 30% year-on-year; net cash position was ₹30.9 billion as at December 31, 2024. US business revenue was ₹24.1 billion, up 31% year-on-year; India geography grew 7% and international formulations revenue was ₹5.7 billion, up 16%. Management said it is confident of meeting its growth and profitability aspirations for FY25, and declined to quantify the size of the Sitagliptin government and CVS opportunities. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Feb 2025 | results Results | Integrated Filing- FinancialAI summaryZydus Lifesciences filed its integrated financial filing with the stock exchanges for the quarter and nine months ended December 31, 2024, with the board approval dated February 5, 2025. Standalone revenue from operations for the quarter ended December 31, 2024 was Rs 25,159 million, against Rs 23,713 million a year earlier; nine-month revenue was Rs 92,967 million against Rs 74,863 million. Standalone net profit for the quarter ended December 31, 2024 was Rs 4,706 million, against Rs 4,504 million a year earlier; nine-month net profit was Rs 29,612 million against Rs 20,363 million. The company said its tax expenses for the quarter and nine months are not comparable with prior periods, because it chose not to exercise the option under section 115BAA of the Income Tax Act and re-measured its tax provisions, with the full impact recognised in the quarter. The auditor's review report states nothing has come to its attention indicating material misstatement in the standalone results. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.